FINWIRES · TerminalLIVE
FINWIRES

Leerink Partners Initiates Altimmune at Outperform With $10 Price Target

By

Altimmune (ALT) has an average rating of overweight and mean price target of $16.06, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles